Compare TBPH & EVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | EVLV |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 993.7M | 988.3M |
| IPO Year | N/A | N/A |
| Metric | TBPH | EVLV |
|---|---|---|
| Price | $18.73 | $6.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $27.80 | $9.13 |
| AVG Volume (30 Days) | 601.0K | ★ 3.2M |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.58 | N/A |
| Revenue | $80,327,000.00 | ★ $136,501,000.00 |
| Revenue This Year | $70.78 | $31.08 |
| Revenue Next Year | N/A | $17.33 |
| P/E Ratio | $32.19 | ★ N/A |
| Revenue Growth | 27.12 | ★ 43.16 |
| 52 Week Low | $7.90 | $2.64 |
| 52 Week High | $20.33 | $8.91 |
| Indicator | TBPH | EVLV |
|---|---|---|
| Relative Strength Index (RSI) | 58.73 | 50.77 |
| Support Level | $18.39 | $6.10 |
| Resistance Level | $20.32 | $6.35 |
| Average True Range (ATR) | 0.87 | 0.33 |
| MACD | -0.05 | 0.11 |
| Stochastic Oscillator | 53.71 | 89.34 |
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Evolv Technologies Holdings Inc offers an AI-based touchless security screening. Its touchless security screening systems use artificial intelligence software, cloud services, and sensors to reliably detect dangerous weapons while ignoring harmless items like cell phones, laptops, and keys. It offers products for purchase under a multi-year security-as-a-service subscription pricing model that delivers ongoing value to customers, generates predictable revenue, and creates expansion and upsell opportunities. The firm operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.